Literature DB >> 16785604

Immune modulation by estrogens: role in CNS HIV-1 infection.

Melinda E Wilson1, Filomena O Dimayuga, Janelle L Reed, Thomas E Curry, Carol F Anderson, Avindra Nath, Annadora J Bruce-Keller.   

Abstract

Experimental and epidemiological data suggest that estrogen can be protective in both brain injury and infection. While estrogens can act directly on neurons to promote neuronal survival, estrogen also has antiinflammatory properties that may contribute to overall neuroprotection. Accordingly, estrogens may have particular relevance in chronic neuroimmune disorders such as HIV dementia. As AIDS is now a leading cause of death among women in their reproductive years, understanding the role that female sex hormones might play in the physiology of HIV-1 infection is especially critical. Indeed, there is accumulating evidence that many manifestations of HIV differ in women. For instance, it is now well established that women present with a lower viral titer at the time of seroconversion, have lower HIV viral loads compared to men at similar stages of disease, and may have altered disease progression during pregnancy. Conversely, while epidemiological studies suggest that women may be more vulnerable to certain late-stage AIDS-related illnesses including HIV dementia, there is accumulating data that strongly suggest an estrogen-deficient state is associated with long-term HIV infection in some women. Evaluated as a whole, existing evidence indicates that estrogen can directly protect neurons from damage, can modulate brain inflammation, and could act to maintain low titers of the HIV-1 virus. Accordingly, it can be hypothesized that maintenance of serum estradiol levels could decrease the incidence of HIV dementia and other AIDS-related neurological syndromes in HIV-1 positive women. In this article, we both summarize current understanding and present new data related to the potential mechanisms whereby estrogen could modulate the mechanics and the consequences of HIV-1 infection in the brain and thereby thwart the development of HIV dementia.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16785604     DOI: 10.1385/ENDO:29:2:289

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  139 in total

1.  Variable progression of HIV-associated dementia.

Authors:  F H Bouwman; R L Skolasky; D Hes; O A Selnes; J D Glass; T E Nance-Sproson; W Royal; G J Dal Pan; J C McArthur
Journal:  Neurology       Date:  1998-06       Impact factor: 9.910

2.  Distribution of brain HIV load in AIDS.

Authors:  C A Wiley; V Soontornniyomkij; L Radhakrishnan; E Masliah; J Mellors; S A Hermann; P Dailey; C L Achim
Journal:  Brain Pathol       Date:  1998-04       Impact factor: 6.508

Review 3.  Adrenal steroid receptors and actions in the nervous system.

Authors:  B S McEwen; E R De Kloet; W Rostene
Journal:  Physiol Rev       Date:  1986-10       Impact factor: 37.312

Review 4.  Long-term hippocampal slices: a model system for investigating synaptic mechanisms and pathologic processes.

Authors:  B A Bahr
Journal:  J Neurosci Res       Date:  1995-10-15       Impact factor: 4.164

5.  Mechanisms of estrogenic protection against gp120-induced neurotoxicity.

Authors:  S A Howard; S M Brooke; R M Sapolsky
Journal:  Exp Neurol       Date:  2001-04       Impact factor: 5.330

Review 6.  Prevention of postmenopausal bone loss and treatment of osteoporosis.

Authors:  Michael Kleerekoper
Journal:  Semin Reprod Med       Date:  2005-05       Impact factor: 1.303

7.  Vascular changes in the cerebral cortex in HIV-1 infection. II. An immunohistochemical and lectinhistochemical investigation.

Authors:  A Büttner; P Mehraein; S Weis
Journal:  Acta Neuropathol       Date:  1996-07       Impact factor: 17.088

8.  17beta-Estradiol inhibits class II major histocompatibility complex (MHC) expression: influence on histone modifications and cbp recruitment to the class II MHC promoter.

Authors:  Jill Adamski; Zhendong Ma; Susan Nozell; Etty N Benveniste
Journal:  Mol Endocrinol       Date:  2004-05-13

9.  Oxidative stress in HIV demented patients and protection ex vivo with novel antioxidants.

Authors:  J Turchan; C B Pocernich; C Gairola; A Chauhan; G Schifitto; D A Butterfield; S Buch; O Narayan; A Sinai; J Geiger; J R Berger; H Elford; A Nath
Journal:  Neurology       Date:  2003-01-28       Impact factor: 9.910

10.  Estrogen blocks inducible nitric oxide synthase accumulation in LPS-activated microglia cells.

Authors:  E Vegeto; G Pollio; P Ciana; A Maggi
Journal:  Exp Gerontol       Date:  2000-12       Impact factor: 4.032

View more
  10 in total

1.  ER-β mediates 17β-estradiol attenuation of HIV-1 Tat-induced apoptotic signaling.

Authors:  Sheila M Adams; Marina V Aksenova; Michael Y Aksenov; Charles F Mactutus; Rosemarie M Booze
Journal:  Synapse       Date:  2010-11       Impact factor: 2.562

Review 2.  Effects of HIV and Methamphetamine on Brain and Behavior: Evidence from Human Studies and Animal Models.

Authors:  Virawudh Soontornniyomkij; James P Kesby; Erin E Morgan; Amanda Bischoff-Grethe; Arpi Minassian; Gregory G Brown; Igor Grant
Journal:  J Neuroimmune Pharmacol       Date:  2016-08-02       Impact factor: 4.147

3.  Β-funaltrexamine inhibits chemokine (CXCL10) expression in normal human astrocytes.

Authors:  Randall L Davis; Subhas Das; Daniel J Buck; Craig W Stevens
Journal:  Neurochem Int       Date:  2013-01-31       Impact factor: 3.921

4.  5α-reduced progestogens ameliorate mood-related behavioral pathology, neurotoxicity, and microgliosis associated with exposure to HIV-1 Tat.

Authors:  Jason J Paris; ShiPing Zou; Yun K Hahn; Pamela E Knapp; Kurt F Hauser
Journal:  Brain Behav Immun       Date:  2016-01-13       Impact factor: 7.217

Review 5.  Methamphetamine and Cannabis: A Tale of Two Drugs and their Effects on HIV, Brain, and Behavior.

Authors:  Rowan Saloner; Jerel Adam Fields; Maria Cecilia Garibaldi Marcondes; Jennifer E Iudicello; Sofie von Känel; Mariana Cherner; Scott L Letendre; Marcus Kaul; Igor Grant
Journal:  J Neuroimmune Pharmacol       Date:  2020-09-15       Impact factor: 4.147

Review 6.  Neurotoxic profiles of HIV, psychostimulant drugs of abuse, and their concerted effect on the brain: current status of dopamine system vulnerability in NeuroAIDS.

Authors:  Mark J Ferris; Charles F Mactutus; Rosemarie M Booze
Journal:  Neurosci Biobehav Rev       Date:  2008-03-18       Impact factor: 8.989

Review 7.  Transgenic mice expressing HIV-1 envelope protein gp120 in the brain as an animal model in neuroAIDS research.

Authors:  Victoria E Thaney; Ana B Sanchez; Jerel A Fields; Arpi Minassian; Jared W Young; Ricky Maung; Marcus Kaul
Journal:  J Neurovirol       Date:  2017-10-26       Impact factor: 2.643

8.  Oestrogen receptor beta ligand: a novel treatment to enhance endogenous functional remyelination.

Authors:  Daniel K Crawford; Mario Mangiardi; Bingbing Song; Rhusheet Patel; Sienmi Du; Michael V Sofroniew; Rhonda R Voskuhl; Seema K Tiwari-Woodruff
Journal:  Brain       Date:  2010-09-21       Impact factor: 13.501

9.  Hormone replacement therapy and risk for neurodegenerative diseases.

Authors:  Richelin V Dye; Karen J Miller; Elyse J Singer; Andrew J Levine
Journal:  Int J Alzheimers Dis       Date:  2012-04-04

10.  Differential Survival for Men and Women with HIV/AIDS-Related Neurologic Diagnoses.

Authors:  Martha L Carvour; Jerald P Harms; Charles F Lynch; Randall R Mayer; Jeffery L Meier; Dawei Liu; James C Torner
Journal:  PLoS One       Date:  2015-06-24       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.